Jun. 29 at 10:00 PM
$ONCY ok Noteable, your valuations are on the premise that Pela becomes the backbone therapy for GI cancers, which wouldn’t happen for 5 years if they continue to have the success that they have shown and as long as they aren’t preceded by something with better results(like what’s happened in MBC and Panc). We are talking about current valuations based on Colorectal, Q4 showing Goblet results in American Soil. We all want this done this year!!!! Going forwards, use current evaluation standards not hopeful evaluations of the future and you won’t be so hated on!
